After cells (5×105 cells/ml) were pretreated with or without 200 µM isorhamnetin for 1 h, they were treated with 100 ng/ml LPS for 1 h. The cells were then washed twice with PBS, fixed in 3.7% paraformaldehyde for 15 min at 25°C, permeabilized with 0.2% Triton X-100 in PBS for 15 min, and blocked for 10 min at 20°C with PBS containing 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA). The cells were then incubated with a primary antibody against NF-κB p65 (dilution, 1:100; cat. no. sc-71675; Santa Cruz Biotechnology, Inc.) at 4°C overnight, followed by incubation with a fluorescein-conjugated anti-mouse immunoglobulin G secondary antibody (dilution, 1:100; cat. no. 62-6511; Molecular Probes; Thermo Fisher Scientific, Inc.) in the dark at 37°C for 40 min. In addition, BV2 cells were pretreated with or without 200 µM isorhamnetin for 30 min, followed by treatment with Alexa Fluor® (AF) 488-conjugated LPS (AF-LPS; 100 ng/ml; Invitrogen; Thermo Fisher Scientific, Inc.) for 6 h, in order to analyze the formation of LPS/TLR4 complexes. Fixed cells were also incubated with anti-TLR4 antibody (1:100; cat. no. ab8376; Abcam, Cambridge, UK) at 4°C for 90 min and were then incubated with AF 594-conjugated secondary antibody (1:100; cat. no. A-11032; Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Nuclei were sequentially stained with DAPI (Sigma-Aldrich; Merck KGaA) solution (2.5 µg/ml). Slides were mounted and fluorescence images were captured under a fluorescence microscope (Zeiss AG, Oberkochen, Germany).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.